The Effect of Mesalamine and Nicotine in the Treatment of Inflammatory Bowel Disease
@article{Bonapace1997TheEO, title={The Effect of Mesalamine and Nicotine in the Treatment of Inflammatory Bowel Disease}, author={Charles R. Bonapace and David A. Mays}, journal={Annals of Pharmacotherapy}, year={1997}, volume={31}, pages={907 - 913} }
OBJECTIVE: To characterize the usefulness of mesalamine and nicotine in the treatment of active ulcerative colitis and inactive Crohn's disease. DATA SOURCES: Citations were selected from the MEDLINE database. Only those involving human subjects, inflammatory bowel disease, and available in English were selected. STUDY SELECTION: Selection criteria consisted of clinical trials and review articles assessing the effects of mesalamine and nicotine in active ulcerative colitis or inactive Crohn's…
11 Citations
An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease
- Medicine, BiologyInflammation Research
- 2000
Nicotine reduced inflammation in the TNBS model of colonic damage confirming the use of nicotine in IBD although the choice of dose requires further investigation.
Clinical economics review: medical management of inflammatory bowel disease
- MedicineAlimentary pharmacology & therapeutics
- 1999
Inflammatory bowel diseases, although they are uncommon and rarely fatal, typically present during the period of economically productive adult life. Patients may require extensive therapeutic…
Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis
- BiologyInflammatory bowel diseases
- 2007
A greater understanding of the pharmacodynamics and kinetics of nicotine in relation to the immune system and enhanced knowledge of gut permeability defects in UC are required to establish the exact protective nature of nicotine and its metabolites in UC.
Transport Mechanisms of Nicotine across the Human Intestinal Epithelial Cell Line Caco-2
- BiologyJournal of Pharmacology and Experimental Therapeutics
- 2002
To characterize the disposition of nicotine in the intestines, intestinal nicotine transport using Caco-2 cells is investigated and specific uptake systems appear to be distinct from organic cation transporters and the transport system for tertiary amines, in terms of its substrate specificity and the pattern of the interaction.
The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.
- Medicine, PsychologyHealth technology assessment
- 2002
Specific interventions included in the review Studies were included if they examined bupropion (150 or 300 mg/day) immediate release and SR formulations, used to aid smoking cessation alone, or as…
Involvement of Neuronal Nicotinic Receptors in Disease
- Biology, Medicine
- 2000
Those diseases in which the association is well established are discussed in detail in this chapter and others, in which nAChR involvement is inferred on the basis of indirect evidence, are mentioned in brief.
A tobacco-specific carcinogen, NNK, enhances AOM/DSS-induced colon carcinogenesis in male A/J mice.
- Medicine, BiologyIn vivo
- 2008
It is suggested that smoking increases the risk of inflammation-related colon cancer development and the effects of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone on colon carcinogenesis were examined using an AOM/dextran sulfate sodium (DSS) mouse model.
Neuronal nicotinic receptors: from structure to pathology
- Biology, ChemistryProgress in Neurobiology
- 2004
Nicotine can skew the characterization of the macrophage type-1 (MPhi1) phenotype differentiated with granulocyte-macrophage colony-stimulating factor to the MPhi2 phenotype.
- BiologyBiochemical and biophysical research communications
- 2009
Nicotine Evoked Currents in Human Primary Sensory Neurons.
- BiologyThe journal of pain : official journal of the American Pain Society
- 2019
References
SHOWING 1-10 OF 32 REFERENCES
Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
- MedicineClinical pharmacy
- 1992
Both rectal mesalamine and oral olsalazine provide clinicians with an effective therapeutic option for the treatment of ulcerative colitis, proctosigmoiditis, and proctitis in patients unresponsive to or intolerant of the effects of sulfasalazine or corticosteroids.
Transdermal nicotine for active ulcerative colitis.
- MedicineThe New England journal of medicine
- 1994
The addition of transdermal nicotine to conventional maintenance therapy improves symptoms in patients with ulcerative colitis.
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
- MedicineGastroenterology
- 1993
Long-term use of mesalamine enemas to induce remission in ulcerative colitis.
- MedicineGastroenterology
- 1990
Transdermal nicotine as maintenance therapy for ulcerative colitis.
- MedicineThe New England journal of medicine
- 1995
Transdermal nicotine alone was no better than placebo in the maintenance of remission of ulcerative colitis, and premature withdrawal due to side effects was more common in the nicotine group.
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
- MedicineThe American journal of gastroenterology
- 1993
The data suggest that controlled-release mesalamine capsules are a safe and effective monotherapy in doses of 2-4 g daily for treating mild to moderately active ulcerative colitis, as well as for inducing remission, regardless of prior oral steroid or sulfasalazine therapy or extent of disease.
Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID)
- MedicineGastroenterology
- 1993
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.
- MedicineGastroenterology
- 1996
After a prednisolone-induces remission in Crohn's disease, mesalamine facilitates steroid withdrawal and, during the postweaning year, may reduce the relapse rate in certain patient subgroups.
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
- MedicineAnnals of internal medicine
- 1991
Colon-targeted oral mesalamine at 2.4 g/d is effective therapy for mildly to moderately active ulcerative colitis and should provide a viable therapeutic alternative to sulfasalazine.
A meta-analysis of the role of smoking in inflammatory bowel disease
- MedicineDigestive diseases and sciences
- 1989
There is no justification for health care providers to change the Surgeon General's recommendations on smoking or tobacco use for ulcerative colitis patients specifically and a review of the literature, meta-analysis of selected studies, and assessment of causality criterion suggest that not smoking and ulceratives colitis and smoking and Crohn's disease are consistent with a causal relationship.